Abstract | BACKGROUND: METHODS: RESULTS:
Pexelizumab significantly reduced the incidence of the composite endpoint of death or myocardial infarction through postoperative day 30 by 28% in patients with two or more risk factors (p = 0.004) and 44% in patients with three or more risk factors (p < 0.001). CONCLUSIONS:
|
Authors | Axel Haverich, Stanton K Shernan, Jerrold H Levy, John C Chen, Michel Carrier, Kenneth M Taylor, Frans Van de Werf, Mark F Newman, Peter X Adams, Thomas G Todaro, Michael van der Laan, Edward D Verrier |
Journal | The Annals of thoracic surgery
(Ann Thorac Surg)
Vol. 82
Issue 2
Pg. 486-92
(Aug 2006)
ISSN: 1552-6259 [Electronic] Netherlands |
PMID | 16863750
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Single-Chain Antibodies
- pexelizumab
|
Topics |
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Cardiopulmonary Bypass
(adverse effects)
- Coronary Artery Bypass
(adverse effects, mortality)
- Double-Blind Method
- Female
- Humans
- Male
- Myocardial Infarction
(prevention & control)
- Single-Chain Antibodies
|